← FDA DRUG APPROVALS

FDA NDA · NDA020872

ALLEGRA HIVES 24HR

fexofenadine hydrochloride

Sponsor: CHATTEM SANOFI

APPLICATION
NDA020872
TYPE
NDA
ORIGINAL APPROVAL
2000-02-25
LATEST ACTION
2023-08-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued, Over-the-counter

Products

ALLEGRA HIVES · ReferenceDiscontinued
FEXOFENADINE HYDROCHLORIDE 60MG · TABLET · ORAL
CHILDREN'S ALLEGRA HIVES · ReferenceDiscontinued
FEXOFENADINE HYDROCHLORIDE 30MG · TABLET · ORAL
ALLEGRA ALLERGY · ReferenceOver-the-counter
FEXOFENADINE HYDROCHLORIDE 180MG · TABLET · ORAL
ALLEGRA HIVES · ReferenceOver-the-counter
FEXOFENADINE HYDROCHLORIDE 180MG · TABLET · ORAL
ALLEGRA ALLERGY · ReferenceOver-the-counter
FEXOFENADINE HYDROCHLORIDE 60MG · TABLET · ORAL
CHILDREN'S ALLEGRA ALLERGY · ReferenceDiscontinued
FEXOFENADINE HYDROCHLORIDE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2023-08-01Manufacturing (CMC) · Supplement 47 · standardLabelAP
2021-10-13Labeling · Supplement 46 · standardLetterAP
2016-05-10Labeling · Supplement 38 · standardLetterAP
2016-03-23Manufacturing (CMC) · Supplement 37 · standardAP
2015-09-24Manufacturing (CMC) · Supplement 35 · standardAP
2015-09-18Manufacturing (CMC) · Supplement 36 · standardAP
2014-12-02Manufacturing (CMC) · Supplement 33 · standardAP
2014-09-12Labeling · Supplement 32 · standardLetterAP
2014-04-16Manufacturing (CMC) · Supplement 31 · standardReviewAP
2013-04-16Manufacturing (CMC) · Supplement 30 · standardAP
2012-08-23Labeling · Supplement 29 · standardLetterAP
2012-02-23Labeling · Supplement 25 · unknownLetterAP
2011-01-24Efficacy · Supplement 23 · standardLetterAP
2008-06-25Labeling · Supplement 18 · standardLetterAP
2005-10-13Efficacy · Supplement 15 · unknownLetterAP
2003-05-12Efficacy · Supplement 11 · priorityLetterAP
2003-05-12Efficacy · Supplement 3 · standardLetterAP
2002-12-10Manufacturing (CMC) · Supplement 9 · standardReviewAP
2002-10-10Manufacturing (CMC) · Supplement 10 · standardReviewAP
2002-02-20Manufacturing (CMC) · Supplement 8 · standardReviewAP
2001-07-11Labeling · Supplement 7 · standardLetterAP
2001-05-30Manufacturing (CMC) · Supplement 4 · standardReviewAP
2001-01-05Manufacturing (CMC) · Supplement 5 · standardReviewAP
2000-04-14Manufacturing (CMC) · Supplement 1 · standardReviewAP
2000-03-21Manufacturing (CMC) · Supplement 2 · standardReviewAP
2000-02-25Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →